Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #67 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Unichem Laboratories Limited (this stock) | 3,742 | 22.5 | 9.3% | 9.1% | — | 62 | 77 | 84 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 633 | 49 | 41 | ₹ |
| March 31, 2026 | 575 | 19 | 11 | ₹ |
| Dec. 31, 2025 | 521 | 293 | 264 | ₹ |
| Sept. 30, 2025 | 579 | -11 | -12 | ₹ |
| June 30, 2025 | 527 | -9 | -10 | ₹ |
| March 31, 2025 | 587 | 58 | 53 | ₹ |
| Dec. 31, 2024 | 533 | 62 | 58 | ₹ |
| Sept. 30, 2024 | 462 | 33 | 30 | ₹ |
| June 30, 2024 | 446 | 15 | 9 | ₹ |
| March 31, 2024 | 432 | -126 | -129 | ₹ |
| Dec. 31, 2023 | 434 | 84 | 84 | ₹ |
| Sept. 30, 2023 | 416 | -22 | -24 | ₹ |
| June 30, 2023 | 423 | 2 | -1 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,202 | 292 | 253 |
| March 31, 2025 | 2,111 | 155 | 138 |
| March 31, 2024 | 1,705 | -62 | -70 |
| March 31, 2023 | 1,343 | -176 | -202 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 4 | 192 | 2 | 123 | -119 |
| March 31, 2025 | -7 | -241 | 184 | 137 | -144 |
| March 31, 2024 | 17 | 50 | -106 | 23 | -6 |
| March 31, 2023 | -85 | 203 | -81 | 44 | -129 |
| March 31, 2022 | -260 | 100 | 191 | 127 | -387 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 3,737 | 2,717 | 2,703 | 430 | 39 | 2,197 | 886 | 289 | 1,204 | 975 |
| March 31, 2025 | 3,569 | 2,451 | 2,437 | 369 | 61 | 2,029 | 992 | 90 | 1,279 | 989 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
